Search

Abstract Background Cardiovascular and renal adaptation in neonates with Respiratory Distress Syndrome (RDS) and Transient Tachypnea of the Newborn (TTN) may be different. Methods Neonates ≥32 weeks were diagnosed with RDS or TTN based on clinical, radiologic and lung sonographic criteria. Weight loss, feeding, urine output, and sodium levels were recorded for the first 3 days, and serial ultrasounds assessed central and organ Doppler blood flow. A linear mixed model was used to compare the two groups. Results Twenty-one neonates were included, 11 with TTN and 10 with RDS. Those with RDS showed less weight loss (− 2.8 +/− 2.7% versus − 5.6 +/− 3.4%), and less enteral feeds (79.2 vs 116 ml/kg/day) than those with TTN, despite similar fluid prescription. We found no difference in urine output, or serum sodium levels. Doppler parameters for any renal or central parameters were similar. However, Anterior Cerebral Artery maximum velocity was lower (p = 0.03), Superior Mesenteric Artery Resistance Index was higher in RDS, compared to TTN (p = 0.02). Conclusion In cohort of moderately preterm to term neonates, those with RDS retained more fluid and were fed less on day 3 than those with TTN. While there were no renal or central blood flow differences, there were some cerebral and mesenteric perfusion differences which may account for different pathophysiology and management.

Background: Cardiovascular and renal adaptation in neonates with Respiratory Distress Syndrome (RDS) and Transient Tachypnea of the Newborn (TTN) may be different.Methods: Neonates ≥32 weeks were diagnosed with RDS or TTN based on clinical, radiologic and lung sonographic criteria. Weight loss, feeding, urine output, and sodium levels were recorded for the first 3 days, and serial ultrasounds assessed central and organ Doppler blood flow. A linear mixed model was used to compare the two groups.Results: Twenty-one neonates were included, 11 with TTN and 10 with RDS. Those with RDS showed less weight loss (- 2.8 +/- 2.7% versus - 5.6 +/- 3.4%), and less enteral feeds (79.2 vs 116 ml/kg/day) than those with TTN, despite similar fluid prescription. We found no difference in urine output, or serum sodium levels. Doppler parameters for any renal or central parameters were similar. However, Anterior Cerebral Artery maximum velocity was lower (p = 0.03), Superior Mesenteric Artery Resistance Index was higher in RDS, compared to TTN (p = 0.02).Conclusion: In cohort of moderately preterm to term neonates, those with RDS retained more fluid and were fed less on day 3 than those with TTN. While there were no renal or central blood flow differences, there were some cerebral and mesenteric perfusion differences which may account for different pathophysiology and management. [ABSTRACT FROM AUTHOR]

The article presents the discussion on high index of suspicion required for urinary tract infections (UTI) detection in the neonatal intensive care unit. Topics include suspected infections based on bagged samples requiring follow-up by either clean catch, urethral catheterization, or suprapubic aspiration (SPA); and contraindications including local skin infection, bowel distension, and, particularly, an empty bladder.

The article focuses on ankyloglossia, or tongue-tie, which is a congenital oral anomaly caused by a very short, thick lingual frenulum, which may decrease tongue mobility. Frenulum is a membrane that connects the underside of the tongue to the floor of the mouth. It is stated that a torn frenulum without frenotomy history in a small infant may be due to potential physical abuse.

Competing Interests: Competing interests: The authors are involved in a research project supported by the MSI Foundation and the American College of Gastroenterology regarding improving clinical pathways in IBD care during pregnancy. Cynthia Seow has received honoraria as an advisory board member for Janssen Pharmaceutical, AbbVie, Shire, Actavis, Takeda Canada and Ferring Pharmaceuticals; speaker fees from Janssen Pharmaceutical and AbbVie; and research and educational support from Janssen Pharmaceutical and AbbVie. No other competing interests were declared.